Department of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, ND, USA.
Department of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, ND, USA.
Nanomedicine. 2021 Apr;33:102357. doi: 10.1016/j.nano.2020.102357. Epub 2021 Jan 15.
Obesity induced chronic low-level inflammation is strongly associated with the development of insulin resistance and progression of type-2 diabetes. Systemic treatment with anti-inflammatory therapeutics requires high doses and is associated with serious adverse effects owing to generalized suppression of the immune system. Here we study localized knockdown of pro-inflammatory adipocytokines in adipose tissue macrophages (ATMs) and adipocytes using RNA interference for the treatment of insulin resistance. Chitosan nanomicelles conjugated to ATM and adipocyte targeting ligands were used to transfect short hairpin RNA (shRNA) against tumor necrosis factor-α (TNFα) and monocyte chemoattractant protein-1 (MCP-1). Subcutaneous administration of nanomicellar/pDNA polyplexes in obese-diabetic mice resulted in decreased concentration of pro-inflammatory cytokines TNFα, MCP-1, IL-6, and IL-1β along with increased concentration of insulin-sensitizing adipokine adiponectin. Downregulation of inflammatory cytokines resulted in improved insulin sensitivity and glucose tolerance for up to six-weeks following single dose, compared to untreated obese-diabetic mice.
肥胖引起的慢性低度炎症与胰岛素抵抗的发展和 2 型糖尿病的进展密切相关。全身使用抗炎治疗药物需要大剂量,并且由于免疫系统的普遍抑制而存在严重的不良反应。在这里,我们研究了使用 RNA 干扰在脂肪组织巨噬细胞(ATMs)和脂肪细胞中局部敲低促炎脂肪细胞因子,以治疗胰岛素抵抗。壳聚糖纳米胶束与 ATM 和脂肪细胞靶向配体结合,用于转染针对肿瘤坏死因子-α(TNFα)和单核细胞趋化蛋白-1(MCP-1)的短发夹 RNA(shRNA)。在肥胖糖尿病小鼠中皮下给予纳米胶束/pDNA 超分子复合物,可降低促炎细胞因子 TNFα、MCP-1、IL-6 和 IL-1β的浓度,同时增加胰岛素敏化脂肪因子脂联素的浓度。与未治疗的肥胖糖尿病小鼠相比,单次给药后长达 6 周,炎症细胞因子的下调可改善胰岛素敏感性和葡萄糖耐量。